3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Endometrial Neoplasms
1
Adenomyosis
1
Interventions
Biopsy
12
Peripheral Blood Stem Cell Transplantation
9
Cyclophosphamide
9
fludarabine phosphate
8
Whole-Body Irradiation
8
Polymerase Chain Reaction
7
Tacrolimus
6
Mycophenolic Acid
6
Gene Expression Profiling
6
Colposcopy
6
Busulfan
6
Microarray Analysis
5
Immunohistochemistry
5
Epoetin Alfa
5
Celecoxib
5
Aminolevulinic Acid
5
Sulindac
4
Selenium
4
Methotrexate
4
Melphalan
4
Cyclosporine
4
Cetuximab
4
Antilymphocyte Serum
4
Vaginal Smears
3
Imiquimod
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Etoposide
3
Eflornithine
3
Darbepoetin alfa
3
Comparative Genomic Hybridization
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precancerous Conditions
×
Robotic Surgical Procedures
×
Other neoplasm
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled